| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | Orthogonal ribosome evolved | JP2009538781 | 2007-11-28 | JP5307020B2 | 2013-10-02 | ジェイソン チン; カイハン ワン; ハインツ ノイマン |
| There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules. | ||||||
| 22 | Cell surface display of proteins of interest, screening, and production | JP2010500980 | 2008-03-26 | JP2010522561A | 2010-07-08 | ダーサ リポフシェク，; ジェームス エー． レイクストロー， |
| 本発明の局面は、人工ポリペプチドを細胞表面にディスプレイするための組成物および方法を提供する。 本発明の局面により、固定化ポリペプチドを分泌させ、１つまたは複数の関心対象の機能的または構造的な特性を有する１つまたは複数の変異体を同定することができる。 本発明の局面は、関心対象の機能的または構造的な特性を有する人工のタンパク質またはタンパク質変異体を産生するための組成物および方法を提供する。 本発明の局面は、人工タンパク質を宿主細胞上に発現させ、ディスプレイする方法を含む。 本発明の局面は、核酸コンストラクト、発現されたタンパク質、宿主細胞、および／または単離されたタンパク質を含む。 | ||||||
| 23 | Obtained by a combination of evolution and rational design, novel microorganisms for the production of 1,2-propanediol | JP2009554045 | 2008-03-21 | JP2010521958A | 2010-07-01 | フィリップ、スカイユ; フランソワ、フェルケ; ライナー、フィゲ |
| 本発明は、炭素源から１，２−プロパンジオールを製造するための微生物株を製造することを目的とする進化と合理的設計を組み合わせた新規な方法に関する。 該方法は、始原株を適切な増殖培地中、選択圧下で増殖させること（該始原細菌株は、始原株において進化を促進するための、ｔｐｉＡ遺伝子の発現の減弱、およびメチルグリオキサールの乳酸への変換に関与する少なくとも１つの遺伝子の発現の減弱を含む）、次に、１，２プロパンジオールの生産率が高まった進化株を選択および単離すること、その後、その進化株において機能的ｔｐｉＡ遺伝子を再構築することを含む。 本発明はまた、得られたもののような進化株に関し、それは副生成物無しに、最良の可能性ある収率で、炭素源の１，２−プロパンジオールへの変換を至適化するためにさらに遺伝的に改変することができる。 | ||||||
| 24 | Way to get a new life form | JP2003510814 | 2002-07-08 | JP4494776B2 | 2010-06-30 | マッツェル，ディディエ; マルリエール，フィリップ; ムッツェル，ルペルト |
| 25 | Orthogonal ribosome evolved | JP2009538781 | 2007-11-28 | JP2010510798A | 2010-04-08 | ジェイソン チン; ハインツ ノイマン; カイハン ワン |
| There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules. | ||||||
| 26 | A method for the evolution adapted to the continuous purpose of the protein in the invitro | JP2008525458 | 2006-08-07 | JP2009504145A | 2009-02-05 | リス ミヒャエル |
| 本発明は、ｉｎ ｖｉｔｒｏ進化方法におけるタンパク質の変異体の製造方法であって、次の工程：（Ａ）次のものを含有するｉｎ ｖｉｔｒｏ発現系の作成工程、（ｉ）変異すべきタンパク質Ｙをコードする核酸配列Ｓ、（ｉｉ）タンパク質Ｙ及び／又は少なくとも１種のこの変異体Ｙに結合することができる目的分子Ｘ 1 、（ｉｉｉ）核酸配列Ｓを転写することができるＲＮＡポリメラーゼ（Ｐｏｌ）、（ｉｖ）核酸配列Ｓの転写産物を逆転写することができる逆転写酵素（ＲＴ）、その際、目的分子ＸはＰｏｌに、そしてタンパク質ＹはＲＴにカップリングしているか、又は目的分子ＸはＲＴに、そしてタンパク質ＹはＰｏｌにカップリングしている、（Ｂ） タンパク質Ｙの変異体Ｙ及び、これをコードする核酸配列Ｓ′の形成下での転写、逆転写及び翻訳を可能にし、かつ、目的分子Ｘのための改善された結合特性を有する変異体Ｙの形成を促進する条件下での、（Ａ）からのｉｎ ｖｉｔｒｏ発現系のインキュベーション工程、（Ｃ）Ｘに対する結合のための改善された結合特性を有する変異体Ｙの単離工程及び場合により特性決定工程及び／又はＹをコードする核酸配列変異体Ｓの単離工程を含む、ｉｎ ｖｉｔｒｏ進化方法におけるタンパク質の変異体の製造方法に関する。 | ||||||
| 27 | SYSTEM FOR CONTINUOUS MUTAGENESIS IN VIVO TO FACILITATE DIRECTED EVOLUTION | US15747282 | 2016-07-25 | US20180216097A1 | 2018-08-02 | Manel CAMPS |
| A system for continuous mutagenesis to facilitate directed evolution, the system including DNA polymerases carrying the novel K54E point mutation, and other point mutations including I709N, A759R, D424A (herein called K54E_LF Pol I) and this methods of use to produce and detect lines where mutagenesis is continuous and does not exhibit the usual decline in mutagenesis with sequential cloning. | ||||||
| 28 | COMPUTER ASSISTED ANTIBODY RE-EPITOPING | US15531308 | 2015-11-25 | US20180068055A1 | 2018-03-08 | Yanay OFRAN; Guy NIMROD; Sharon FISCHMAN; Asael HERMAN |
| The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated. | ||||||
| 29 | Cell Surface Display, Screening and Production of Proteins of Interest | US15471604 | 2017-03-28 | US20170261506A1 | 2017-09-14 | James A. Rakestraw; Stan I. Letovsky; Shaun Lippow |
| Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | ||||||
| 30 | ANTIBODY LIKE PROTEIN | US14497320 | 2014-09-25 | US20160222065A9 | 2016-08-04 | Mike Longo; Rajika Perera |
| A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences. | ||||||
| 31 | DESIGN OF MOLECULES | US14986516 | 2015-12-31 | US20160196412A1 | 2016-07-07 | Andrew Lee Hopkins; Jérémy Besnard |
| A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1-In) from the population (PG=0); and evaluating members (I1-In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n. | ||||||
| 32 | ANTIBODY LIKE PROTEIN | US14497320 | 2014-09-25 | US20160090400A1 | 2016-03-31 | Mike Longo; Rajika Perera |
| A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences. | ||||||
| 33 | METHODS AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE HAVING AN INTERMOLECULAR INTERACTION WITH A TARGET OF INTEREST | US14923855 | 2015-10-27 | US20160046929A1 | 2016-02-18 | Ilan MORAD; Hanan ITZHAKI |
| This invention provides, in one embodiment, a recombinant virus or a recombinant virus library wherein each virus comprises a protein involved in viral attachment or infection, a polypeptide which differs by at least a single amino acid from another peptide or polypeptide in the library, and a modified cleavage site that is proximal to the peptide and the protein, wherein the cleavage site is modified such that a compound mediating cleavage has a reduced binding affinity for it as compared to a non-modified cleavage site. The invention further provides a target of interest complex comprising a protease, a target of interest involved in an intermolecular interaction, and a flexible linker that attaches the protease and target of interest. The invention further provides uses thereof, including a method for identifying a peptide which has an intermolecular interaction with a target of interest or identifying the agonistic or antagonistic feature of a peptide that has an intermolecular reaction with a target of interest. | ||||||
| 34 | Generation of library of soluble random polypeptides linked to mRNA | US12525437 | 2008-02-12 | US09080256B2 | 2015-07-14 | Richard B Williams |
| Methods and compositions are provided for producing libraries of soluble random polypeptides. In the methods, the fraction of hydrophilic residues in the polypeptide is controlled so as to maintain the solubility of the polypeptide constructs. | ||||||
| 35 | Cell surface display, screening and production of proteins of interest | US12546583 | 2009-08-24 | US08722586B2 | 2014-05-13 | James A. Rakestraw; Stan I. Letovsky; Shaun Lippow |
| Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | ||||||
| 36 | High-Throughput Immune Sequencing | US13878400 | 2011-10-11 | US20130296535A1 | 2013-11-07 | George M. Church; Francois Vigneault; Uri Laserson; Ido Bachelet |
| Methods and compositions for determining and/or monitoring the immune state of an individual are provided. | ||||||
| 37 | STRUCTURE-ACTIVITY RELATIONSHIPS | US13764252 | 2013-02-11 | US20130157900A1 | 2013-06-20 | Emily Mundorff; Simon Christopher Davis; Gjalt W. Huisman; Anke Krebber; John H. Grate |
| The present disclosure relates to compositions and methods for screening a plurality of polypeptide variants. | ||||||
| 38 | DESIGN OF MOLECULES | US13510599 | 2010-11-22 | US20120265514A1 | 2012-10-18 | Andrew Lee Hopkins; Jérémy Besnard |
| A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1−In) from the population (PG=0); and evaluating members (I1−In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n. | ||||||
| 39 | NEW MICRO-ORGANISMS FOR THE PRODUCTION OF 1,2-PROPANEDIOL OBTAINED BY A COMBINATION OF EVOLUTION AND RATIONAL DESIGN | US12532405 | 2008-03-21 | US20100285547A1 | 2010-11-11 | Philippe Soucaille; Francois Voelker; Rainer Figge |
| The present invention concerns a new method combining evolution and rational design for the preparation of a strain of micro-organism for the production of 1,2-propanediol from a carbon source.The said method comprises: growing an initial strain under selection pressure in an appropriate growth medium, said initial bacterial strain comprising an attenuation of the expression of the tpiA gene and an attenuation the expression of at least one gene involved in the conversion of methylglyoxal to lactate, in order to promote evolution in said initial strain, then selecting and isolating the evolved strain having an increased 1,2 propanediol production rate, then reconstructing a functional tpiA gene in the evolved strain; The present invention also concerns the evolved strain such as obtained, that may be furthermore genetically modified in order to optimize the conversion of a carbon source into 1,2-propanediol without by-products and with the best possible yield. | ||||||
| 40 | Cell Surface Display, Screening and Production of Proteins of Interest | US12546583 | 2009-08-24 | US20100267057A1 | 2010-10-21 | James A. Rakestraw; Stan I. Letovsky; Shaun Lippow |
| Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | ||||||
QQ群二维码
意见反馈
意见反馈